Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Arch Cardiovasc Dis ; 117(5): 358-378, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38762344

RESUMO

Low-density lipoprotein cholesterol has been established as a powerful cardiovascular risk factor; its reduction provides a clinical benefit in primary cardiovascular prevention, irrespective of the characteristics of the patients treated. It is useful to tailor low-density lipoprotein cholesterol targets according to the magnitude of cardiovascular risk (low, high or very high) in order to reduce the cardiovascular risk as fully as possible. In order to provide a uniform approach, it is necessary to propose recommendations for good practice, defining strategies for reducing low-density lipoprotein cholesterol. It is also necessary to know their merits, to analyse their practical limits and to propose adaptations, taking into account limitations and national specifics. This position paper aims to analyse the contribution and limits, as well as the adaptation to French practice, of 2019 and 2021 European Society of Cardiology recommendations for the management of lipid variables and cardiovascular prevention.


Assuntos
Biomarcadores , Doenças Cardiovasculares , LDL-Colesterol , Consenso , Dislipidemias , Fatores de Risco de Doenças Cardíacas , Prevenção Primária , Humanos , Doenças Cardiovasculares/prevenção & controle , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/sangue , Biomarcadores/sangue , LDL-Colesterol/sangue , Dislipidemias/sangue , Dislipidemias/diagnóstico , Dislipidemias/terapia , Dislipidemias/tratamento farmacológico , Dislipidemias/epidemiologia , Medição de Risco , Hipolipemiantes/uso terapêutico , Resultado do Tratamento , França , Cardiologia/normas
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa